Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Significant Decrease in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 56,253 shares, a decline of 55.4% from the July 30th total of 126,080 shares. Based on an average trading volume of 140,397 shares, the short-interest ratio is currently 0.4 days. Approximately 2.5% of the company’s stock are sold short.

Lakewood-Amedex Biotherapeutics Price Performance

NASDAQ:LABT traded down $0.19 during mid-day trading on Friday, reaching $2.30. The company’s stock had a trading volume of 95,736 shares, compared to its average volume of 145,485. The business’s fifty day simple moving average is $2.54. Lakewood-Amedex Biotherapeutics has a 1 year low of $1.66 and a 1 year high of $98.20. The stock has a market capitalization of $5.45 million and a price-to-earnings ratio of -0.48.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter. As a group, equities analysts forecast that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on LABT shares. Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Weiss Ratings began coverage on Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lakewood-Amedex Biotherapeutics has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.